ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1464	National Cancer Institute	Html	en	Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of malignant mesothelioma.	standard treatment option 0.662037 relatively long survival 0.763744 definitive surgery 0.66758 advanced mesothelioma 0.746687 major symptomatic problems 0.680779 chemotherapy 0.784047 worst prognostic group 0.744191 sarcomatoid mesothelioma 0.794135 bland tumor cells 0.677183 recurrence-free survival 0.667934 clinical trials 0.794592 important prognostic factor. 0.728634 Median survival 0.786141 randomized study 0.677593 patients 0.897231 survival 0.852167 useful immunohistochemical stains 0.67583 CALGB prognostic group 0.748668 progression-free survival rate 0.733148 Cooperative Oncology Group 0.690912 neoadjuvant chemotherapy 0.666321 survival times 0.760237 prognostic value 0.740005 radiation therapy 0.723289	improved survival 0.661891 poorer survival 0.696893 aggressive treatment approaches 0.668925 different treatment modalities 0.670393 aggressive surgical approaches 0.806279 CALGB index 0.684276 mesothelioma diagnoses. 0.716989 Desmoplastic mesothelioma 0.719754 epithelioid mesothelioma 0.727094 adjuvant radiation therapy 0.676072 mesothelioma 0.925011 Advanced Malignant Mesothelioma 0.78476 tissue specimens 0.675675 malignant pleural mesothelioma 0.822532 first-line chemotherapy 0.674756 white blood cell 0.694326 first-line combination chemotherapy 0.748058 recurrent malignant mesothelioma 0.883067 extrapleural pneumonectomy 0.673182 malignant pleural disease 0.743809 large randomized study 0.671727 PDQ summary 0.685413 improved long-term survival 0.756886 prognostic groups 0.660571	CLICK HERE
1727	National Cancer Institute	Html	en	Bone Cancer	A fact sheet about the diagnosis and treatment of cancers that develop in the bones.	benign bone tumors 0.382978 soft tissue 0.317275 osteoid tissue 0.26524 uncommon cancer 0.255981 primary bone cancer 0.577561 cancer cells 0.329155 abnormal bone tissue 0.376855 metastatic cancer 0.262213 bone scan 0.325169 anticancer drugs 0.274172 Cancer Information Service 0.273277 Yes. Cancer 0.261575 tumor causes production 0.259064 healthy bone tissue 0.408981 Yes. Bone cancer 0.36265 Cancer Treatment Research 0.2781 preoperative tumor treatment 0.265675 healthy tissue 0.254742 fibrous tissue 0.263622 clinical trials 0.344137 bone tissue 0.452141 primitive nerve tissue 0.285777 heredity cancer syndromes 0.279206 normal bone tissue 0.410848	Clinical Trials page 0.251984 Ewing Sarcoma Family 0.249697 soft tissue sarcomas 0.285733 incisional biopsy 0.250026 tissue sample 0.258655 blood vessels 0.251489 high-dose external radiation 0.249703 spongy tissue 0.268691 bone marrow 0.344367 cancer centers 0.251332 different types 0.282598 doctor 0.249686 new bone cells 0.361397 bones 0.259461 important treatment option 0.251744 radiation therapy 0.277888 treatment options 0.263715 bone cancer 0.911469 comprehensive cancer information 0.27281 research studies 0.263781 cancerous bone cells 0.36956 bone cancers 0.35903 African American children 0.253491	CLICK HERE
1773	National Cancer Institute	Html	es	Trastornos del sueño (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las causas de los trastornos del sueño de las personas con cáncer y su manejo.	American Academy 0.62007 sleep disturbance 0.546203 Sateia MJ 0.426893 Sleep Disturbance Scale 0.434259 CdV Mejoras 0.428861 mg riesgo 0.50361 National Sleep Foundation 0.473914 Sleep Quality Index 0.466452 Simard S 0.452533 neglected problem 0.428741 sueño mor 0.943385 risk factors 0.426951 sleep-wake disturbances 0.458084 Sleep Disorders 0.45951 Oncol Nurs 0.45478 PDQ Delirium 0.436712 coordinación motriz 0.436956 sueño diario 0.570793 sleep disruption 0.458489 Insomnia Severity Index 0.446987 patients with 0.455594 Hirshkowitz M 0.42487 Pittsburgh Sleep Quality 0.464939 Insomnia Severity 0.454434 sueño frente 0.501612	Roscoe JA 0.426353 Oncol Nurs Forum 0.453234 Morin CM 0.426813 sueño categoría 0.493243 Care Cancer 0.439262 Palesh OG 0.427427 ECA Control 0.495325 Savard J 0.54747 Sleep Medicine review 0.435342 Mustian KM 0.426387 patients based 0.427546 Rochester Cancer Center-Community 0.462263 Clinical Oncology Program 0.450218 sleep regulation 0.427006 sueño nmor 0.697198 Clin Oncol 0.506515 Clin North Am 0.455007 estadio i–iii 0.467766 Center-Community Clinical Oncology 0.451231 psychological associations 0.42745 Cancer Center-Community Clinical 0.464249 Sleep Medicine 0.709305 Med Clin North 0.456379 Sleep Disorders Classification 0.439634	CLICK HERE
1889	National Cancer Institute	Html	es	Tratamiento del cáncer de colon (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de colon.	siguientes procedimientos 0.92972 pequeña cantidad 0.497446 estadio ii 0.856655 tubo recolector 0.46569 rayos x 0.562684 inferior.ampliar procedimiento 0.480242 enlace drugs approved 0.587222 escáner tep 0.457465 proteína llamada factor 0.458005 National Cancer Institute 0.432943 sustancia llamada gadolinio 0.497309 siguientes riesgos 0.425516 Instituto Nacional 0.460477 PDQ Tratamiento 0.671072 estadio iiia 0.656788 antecedentes familiares 0.459139	estadio iiic 0.63832 cáncer.ampliar sigmoidoscopia 0.46788 estadio iiib 0.647408 estadio iia 0.819513 estadio iic 0.81663 células cancerosas.El bevacizumab 0.49983 Physician Data Query 0.524312 Rectal Cancer 0.499997 cuerpo).ampliar anatomía 0.468805 crecer.El ziv-aflibercept 0.437476 antígeno carcinoembrionario 0.577035 PDQ Cánceres 0.540215 colon forma 0.990115 tejidos sanos circundantes 0.470011 Estadio IVA 0.522216 siguientes pruebas 0.469066	CLICK HERE
1995	National Cancer Institute	Html	es	Tratamiento de la histiocitosis de células de Langerhans (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el tratamiento de la histiocitosis de células de Langerhans infantil.	Immunol Cell Biol 0.40642 langerhans cell 0.852012 lesiones hcl 0.406571 with langerhans 0.417161 langerhans cell histiocytosis 0.986891 multisystem langerhans 0.422209 BRAF V600E-negative Langerhans 0.406114 Langerhans-cell histiocytosis 0.403191 cutaneous langerhans 0.405301 células dendríticas mieloides 0.413633 BRAF Mutation Correlates 0.403764 braf mutation 0.404571 pulmonary langerhans 0.409447 pediatric-onset multisystem langerhans 0.405705 HCL multisistémica 0.436981 pulmonary langerhans cell 0.407403 Grois N 0.403041 cell histiocytosis patients 0.407759 Cell Histiocytosis Study 0.404713 cell histiocytosis harboring 0.404154 mutación v600e 0.406931 dendritic cell differentiation 0.403188 mutación braf v600e 0.411753 histiocytosis lesions reveals 0.403971 Arch Dis Child 0.403576	Emile JF 0.403241 epidermal langerhans cells 0.412171 HCL dérmica 0.409229 BRAF V600E 0.436151 Pediatr Blood Cancer 0.419983 lesiones óseas 0.406722 With High-Risk Langerhans 0.411149 mutaciones braf v600e 0.404471 Multiresistant Langerhans Cell 0.407509 mutación braf 0.412372 braf inhibitor 0.402661 Med Pediatr Oncol 0.402927 Clin Oncol 0.402664 with braf 0.403023 células circulantes 0.409275 adult pulmonary langerhans 0.405666 HCL CD1a-positivas 0.409797 Langerhans'-cell histiocytosis 0.405031 High-Risk Langerhans Cell 0.421727 oncogén braf 0.403238 tratamiento inicial.la hcl 0.405836 with epidermal langerhans 0.411581 childhood langerhans 0.408867 French Langerhans 0.405677	CLICK HERE
3446	National Cancer Institute	Html	es	Consumo de cigarrillo: riesgos para la salud y cómo dejar de fumar (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre la investigación y pautas que se enfocan en la prevención y el abandono del tabaquismo.	efectos secundarios comentarios 0.501986 leucemia mieloide 0.427415 metabolitos carcinógenos 0.42791 bupropión marca dosis 0.454219 grupo vareniclina 0.463468 importancia clínica 0.450606 MVL Nicorette DS 0.439222 pruebas directas 0.619014 MVL Nicoderm CQ 0.440426 MVL Commit 0.42718 Sin embargo 0.467903 muertes prematuras 0.469229 largo plazo 0.764238 cessation interventions among 0.449671 Lung Health Study 0.44169 Lancaster T 0.545862 defunciones prematuras 0.434559 bupropión mejora 0.45245 Stead LF 0.482703 orientación mejora 0.429664 bupropión ap 0.446903 Nicotine replacement therapy 0.444158 semanas insomnio 0.443481 vareniclina mejora 0.477582 Estados Unidos 0.989049	polacrilex marca dosis 0.434801 insomnio riesgo 0.427937 smoking cessation 0.872626 salud pública 0.590985 Database Syst Rev 0.689429 abandono gradual versus 0.477395 nicotina marca dosis 0.473496 beneficio hipotético implícito 0.443214 Treating Tobacco Use 0.44172 versus trn 0.451335 MVL Nicorette 0.462807 mejores tasas 0.435725 Community Intervention Trial 0.530278 Marca Dosis Efectos 0.591077 alta calidad 0.516955 efectos secundarios advertencias 0.436485 compuestos carcinógenos 0.426773 tasas promedio 0.433836 aductos carcinógenos 0.42846 planta cytisus laburnum 0.434664 antidepresivo bupropión 0.449342 cuello uterino 0.576293 MVL Nicotrol 0.425887 Surveillance Modeling Network 0.440037	CLICK HERE
3573	National Cancer Institute	Html	en	Immunotherapy: Using the Immune System to Treat Cancer	Immunotherapies are treatments that restore or enhance the immune system’s natural ability to fight cancer. In just the past few years, the rapidly advancing field of cancer immunology has produced several new methods of treating cancer that increase the strength of immune responses against tumors.	abnormal cells 0.352853 CAR T cells 0.324531 cancer cells 0.817652 immune system activity 0.227645 immune responses 0.409806 toxic substance 0.204832 dendritic cells 0.272111 immune system molecules 0.223265 white blood cells 0.307219 activated T cells 0.296761 immune system—research 0.253725 immune response 0.250155 advanced lung cancer 0.212796 cancer treatment vaccine 0.201283 clinical trials 0.278634 tumor cells 0.49599 CD20-expressing cells 0.269956 normal cells 0.295119 human clinical trials 0.248944	antibody-dependent cell-mediated cytotoxicity 0.250246 patients 0.23385 advanced melanoma 0.22903 immune cells 0.680701 immune checkpoint inhibitors 0.313495 FDA-approved checkpoint inhibitors 0.216978 therapeutic antibodies 0.216622 cancer cell death 0.250231 immunotherapy uses proteins 0.212508 CAR T-cell therapy 0.397055 natural killer cells 0.304861 lymphoma cells 0.266327 cells 0.903811 different checkpoint protein 0.207351 modified T cells 0.282987 immune checkpoint proteins 0.3798 existing T cells 0.321978 certain immune cells 0.38886	CLICK HERE
16203	National Cancer Institute	Html	en	Ribociclib Improves Progression-Free Survival for Some Women with Metastatic Breast Cancer	A summary of interim results from a phase III trial testing ribociclib plus letrozole (Femara®) as a first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.	Novartis Pharmaceuticals 0.50861 M.D. 0.440705 Postmenopausal women 0.52856 control group 0.563284 second-line therapy 0.517854 proteins—cyclin-dependent kinase 0.519068 CDK4/6 inhibitor 0.52299 Gabriel N. Hortobagyi 0.621331 ribociclib arm 0.512946 median follow-up 0.54408 significantly more neutropenia 0.507111 overall survival 0.538115 Alexandra Zimmer 0.526907 greater share 0.502287 infections 0.43551 Cancer Research 0.512142 first-line treatment 0.673992 tumor cells 0.508198 median progression-free survival 0.787416 clinical trial 0.51962 significant benefit 0.498831 letrozole 0.459254 ribociclib group 0.78322 first-line therapy 0.552793	disease 0.421331 MD Anderson Cancer 0.627314 progression-free survival 0.953616 placebo group 0.714241 careful monitoring 0.503418 patients 0.470449 planned interim analysis 0.594125 adverse events 0.50283 improvement 0.435679 Medicine 0.420889 higher rate 0.49447 NCI’s Center 0.505585 University 0.421021 favor 0.420251 HER2-negative metastatic breast 0.65043 certain types 0.509753 Texas 0.421011 metastatic breast cancer 0.821955 colleagues 0.422295 New England Journal 0.621204 HER2-negative breast cancer 0.726717 Femara® 0.421383 Dr. Zimmer 0.591472	CLICK HERE
16637	National Cancer Institute	Html	en	Metformin: Can a Diabetes Drug Help Prevent Cancer?	An article about the diabetes drug metformin, which research suggests may help prevent cancer.	metformin derivative 0.623089 cancer treatment 0.490275 study participants 0.484909 Dr. Heckman-Stoddard 0.535865 Family Comprehensive Cancer 0.513801 metformin arm 0.64832 early-phase prevention trials 0.505251 substantially lower risk 0.487063 original metformin formulation 0.653789 extensive laboratory research 0.487291 conventional antidiabetic doses 0.482196 Phase Prevention Trials 0.510585 clinical trials 0.598194 DPP Outcomes Study 0.570815 early-stage breast cancer 0.516459 laboratory studies 0.518492 Cancer Center 0.508828 Dr. Pollak 0.522365 triple-negative breast cancer 0.514736 postmenopausal breast cancer 0.520249 Dr. Zell 0.51558 cancer survivors 0.511148 Diego Moores Cancer 0.510708 metformin treatment 0.637604 large epidemiologic studies 0.500626	breast cancer cells 0.511965 cancer prevention 0.554231 primary cancer 0.48954 certain blood biomarkers 0.485052 cancer outcomes 0.485417 metformin derivatives 0.623142 blood biomarkers 0.487459 smaller prevention trials 0.498934 metformin 0.934872 breast cancer 0.751317 metformin’s effect 0.638135 cancer development 0.510096 early-stage clinical trials 0.564264 metformin’s impact 0.702491 breast cancer recurrences 0.517045 cancer clinical trials 0.527071 Diabetes Prevention Program 0.513336 cancer risk 0.512957 early-phase clinical trial 0.492505 cancer 0.791776 prevention trials 0.556708 diabetes drug metformin 0.743736 cancer incidence 0.513399 Antonio Breast Cancer 0.515009	CLICK HERE
16859	National Cancer Institute	Html	en	Annual Reporting and Auditing	Reporting helps ensure desired results are achieved throughout the grants lifecycle. Learn more about reporting and auditing requirements for cancer research grants.	audit requirements 0.743431 expenditure data 0.682542 recipient organization 0.553305 Interagency Edison 0.55337 specific grant 0.551262 budget period 0.798124 frequent reporting 0.683485 GPO Stock 0.544524 foreign organizations 0.54552 competing project period 0.68277 federal government 0.548657 management staff review 0.661754 federal support 0.55664 Financial operations 0.549474 for-profit hospitals 0.543055 financial expenditure reports 0.726911 NIH Grants Policy 0.987592 financial status 0.557124 NCI Program 0.553741 cash transaction data 0.661127 For-profit organizations 0.556895 individual award requirements 0.714539 recipient organizations 0.564783 multiple PIs 0.556136 award process 0.560959	grants management staff 0.941167 common reports 0.590648 recipients 0.59377 annual basis 0.550363 annual reports 0.571527 grant award 0.582091 different schedule 0.553636 Contact PI 0.548816 federal awards 0.687649 local government audit 0.75977 progress report 0.54964 subsequent budget period 0.690671 eRA Commons 0.887345 grant activity 0.54536 annual audit 0.999887 official accounting records 0.673267 nonprofit organizations 0.546576 NIH support 0.566195 non-competing continuation 0.568684 Financial reports 0.562828 generally accepted government 0.654669 government auditing standards 0.89142 Grants Policy Statement 0.964206 financial related audit 0.753867	CLICK HERE